Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI

Exclusion Criteria

• •Patients with a formal indication for anticoagulation after PPCI (e.g. atrial fibrillation, left-ventricular thrombus, intra-aortic balloon pump, pulmonary embolism, mechanical heart valve)
• •Patients with any indication for chronic anticoagulation
• •Patient with previous lytic treatment
• •Patient with previous coronary artery bypass graft surgery
• •Cardiogenic shock, malignant ventricular arrhythmia, or mechanical complications
• •Any anticoagulation other than bivalirudin started after the procedure before randomization
• •Estimated body weight of \>120 kg or \<45kg
• •BP ≥180/110mmHg at randomization
• •Any bleeding diathesis or severe hematologic disease or history of intracerebral mass, aneurysm, arteriovenous malformation, recent (\<6months) ischemic stroke or TIA, recent (\<6months) intracranial hemorrhage or, gastrointestinal or genitourinary bleeding within the past 2 weeks
• •History of heparin-induced thrombocytopenia
• •Suspected acute aortic dissection (AAD)
• •Major surgery within 1 month
• •A planned elective surgical procedure that would necessitate an interruption in treatment with P2Y12 inhibitors in the next 6 months after enrollment
• •Known PLT≤100×109 or HGB≤10g/L
• •Known transaminase \>3-fold ULN, or CCr\<30ml/min
• •Known allergy to any study drug
• •Pregnancy or lactation
• •Noncardiac coexisting conditions that could limit life expectancy to less than 1 year
• •Current participation in an investigational drug or device trial